Business Standard

TB Alliance grants licence to Macleods for manufacturing anti-TB drug


Press Trust of India New Delhi
TB Alliance, a not-for-profit organisation, on Monday said it has granted a non-exclusive licence to manufacture anti-TB drug pretomanid to Macleods Pharmaceuticals Ltd.
Macleods has agreed to commercialise the anti-tuberculosis (TB) medicine in about 140 countries and territories, including India, after getting the regulatory approvals, TB Alliance said in a statement.
"We are proud to partner with Macleods, which has a strong record of delivering high-quality, affordable tuberculosis medicines," TB Alliance President and CEO Mel Spigelman said.
TB Alliance is committed to ensuring an affordable, sustainable and competitive market for all its new TB products, he added.
"This important collaboration with TB Alliance will ensure accessibility of pretomanid in countries where it is needed the most," Macleods Business Development Director Vijay Agarwal said.
TB Alliance has earlier collaborated with Macleods on the introduction of child-friendly formulations of first-line TB medicines, the statement said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 28 2019 | 6:10 PM IST

Explore News